FEELM Issues Press Statement on FDA’s First Vaping Product Authorization
FEELM made the following statement regarding the FDA’s first vaping product authorization:
On Oct 12, 2021, the U.S Food and Drug Administration (FDA) has granted marketing orders for Vuse Solo, closed electronic nicotine delivery system (ENDS) and accompanying tobacco-flavored e-liquid pods of R.J.Reynolds Vapor, allowing the products to be legally sold in the United States. It is the first set of ENDS products authorized by the FDA through the Premarket Tobacco Product Application (PMTA), marking a milestone for the global vaping regulations. It sends a positive message to the global atomization industry for it is the first time that a vaping product is authorized by a health regulator, indicating that FDA has embraced vaping’s potential to improve public health.
The scientific data submitted by R.J.Reynolds Vapor has demonstrated the health benefits of Vuse tobacco-flavored ENDS. According to FDA, “under the PMTA pathway, manufacturers must demonstrate to the agency that marketing of the new tobacco product would be appropriate for the protection of the public health. “
Remarkably, the authorization only applies to the tobacco-flavored cartridge and FDA has simultaneously issued marketing denial orders (MDOs) for other flavors submitted under Vuse Solo. It could represent a direction of vaping regulations of FDA and other regulators: ENDS products shall be only used as a tool to help smoking cessation while preventing a new generation of nicotine addiction. Since the U.S federal flavor ban went into effective in February 2020, it has been clear that FDA is highly concerned with the alleged association between youth vaping and flavors.
Meanwhile, Vuse Alto, another flagship product of R.J.Reynolds Vapor is awaiting further review from FDA. In September 2020, the company has completed the PMTA submissions of Vuse Alto, which is powered by FEELM ceramic coil. The authorization of Vuse Solo by FDA is a sign of more authorizations of ENDS products to come.
Vuse has become the fastest-growing vapor brand. It has accounted for over 26% market share in the top five markets, being the market leader in Canada, the UK, France and Germany. In the U.S, e-cig category volume growth slightly decelerates while Vuse continues to outperform in 2021, making it the second largest and fastest-growing market player in this country. As the industry’s first vapor brand authorized by FDA, Vuse is expected to continue its growth momentum by virtue of its first-mover advantage and its industry-leading ceramic coil.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211021006142/en/
Contact information
Media:
FEELM
feelm@smoorecig.com
Frankie Chen, (+86)13530848319, frankie.chen@smoorecig.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Global Registry Data Show Meaningful Overall Survival Benefit in Patients with Advanced Cutaneous T-cell Lymphoma (CTCL) treated with POTELIGEO (mogamulizumab)22.10.2025 10:30:00 EEST | Press release
Kyowa Kirin International (KKI), a wholly owned subsidiary of Kyowa Kirin Co., Ltd. (TSE:4151, Kyowa Kirin), a Japan-based global specialty pharmaceutical company, and the University Hospitals Birmingham NHS Foundation Trust, today announced new overall survival (OS) insights from the PROCLIPI (PROgnostic Cutaneous Lymphoma International Prognostic Index) Study aligning with previous findings that suggest mogamulizumab may offer meaningful OS benefit for patients living with mycosis fungoides (MF) and Sézary syndrome (SS), two rare conditions and subtypes of cutaneous T-cell lymphoma (CTCL).2 Key findings2: For patients with advanced-stage MF and SS (n=371), the median overall survival from the onset of treatment was higher for patients treated with mogamulizumab (n=72) at 64 months compared with those not receiving mogamulizumab (n=175) at 54 months (p<0.01). Patients treated with mogamulizumab showed a trend toward improved OS compared to those not receiving mogamulizumab across risk
World First: H-UKR 0% Clinker Cement Obtains Technical Assessment (ATec) for Wind Turbine Foundations22.10.2025 09:00:00 EEST | Press release
Hoffmann Green Cement Technologies (ISIN: FR0013451044, Ticker: ALHGR) (“Hoffmann Green Cement” or the “Company”), an industrial player committed to the decarbonation of the construction sector that designs and markets innovative cold produced, clinker-free cements, today announces that it has obtained a Technical Assessment (ATec) validating the use of its H-UKR decarbonized cement for wind turbine foundations. This unprecedented recognition, a world first for a 0% clinker cement, certifies that the H-UKR solution meets the highest standards of sustainability, safety, and performance for particularly rigorous applications such as wind power. A strategic step towards new markets This certification marks another key milestone for Hoffmann Green, enabling it to further accelerate its growth in the renewable energy market from 2026 and beyond. Obtaining this ATec certification paves the way for new commercial opportunities in this sector, strengthening its insurability with project owners
Takeda Enters Global Strategic Partnership with Innovent Biologics to Bolster Oncology Pipeline with Next-Generation Investigational Medicines for Treatment of Solid Tumors22.10.2025 03:25:00 EEST | Press release
Takeda (TSE:4502/NYSE:TAK) today announced that it has entered into a license and collaboration agreement with Innovent Biologics (HKEX: 01801) for the development, manufacturing and commercialization of two late-stage oncology medicines, IBI363 and IBI343, worldwide outside of Greater China.* IBI363 is being evaluated in non-small cell lung and colorectal cancers and has shown potential efficacy in additional solid tumor types. IBI343 is being evaluated in gastric and pancreatic cancers. Takeda will also receive an exclusive option to license global rights outside of Greater China for IBI3001, an early-stage investigational medicine. “IBI363 and IBI343, two next-generation investigational medicines, have the potential to address critical treatment gaps for patients with a range of solid tumors,” said Teresa Bitetti, President, Global Oncology Business Unit, Takeda. “We are energized by the progress made by Innovent to date and look forward to collaborating to unlock the potential of t
YES Selected to Deliver Full Portfolio of Advanced Packaging Tools for Glass Panel AI and HPC Applications by a Leading AI Infrastructure Supplier21.10.2025 22:16:00 EEST | Press release
Yield Engineering Systems (YES), a leading provider of advanced process equipment for AI and high-performance computing (HPC) semiconductor applications, today announced that it has received multiple tool orders from a global leader in AI infrastructure solutions. The orders span YES’s portfolio of Dry and Wet process systems and will support panel-level manufacturing on glass substrates for next-generation data center and HPC packaging. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251020459437/en/ YES VertaCure, VertaPrime, VeroFlex, TersOra, and SURE systems. The systems will be deployed in advanced packaging lines dedicated to hyperscale AI workloads, including training, inference, networking, and co-packaged optics. This award marks a significant milestone in the industry's shift toward glass-based 2.5D and 3D packaging as system performance, density, and thermal requirements escalate. YES will supply a full suite of s
Esri and UNFPA Extend Strategic Partnership to Support 2030 Census Round21.10.2025 22:09:00 EEST | Press release
Esri, the global leader in location intelligence, today announced the extension of its strategic partnership with the United Nations Population Fund (UNFPA) in support of the 2030 census round. Building on a successful collaboration during the 2020 census round, the partnership aims to embed geographic information system (GIS) technology into all phases of census work. By leveraging GIS, national statistics and census offices will gain access to more authoritative, location-enabled data and faster, more efficient methods of planning, collection, and dissemination. “National census projects can often involve mapping an entire country,” said Linda Peters, Esri global business development manager. “GIS is becoming crucial for every step of a census but deploying it is new to many national statistical offices. We are happy to provide the resources that can enable this large-scale feat of authoritative data collection and communication.” The integration of location intelligence into census
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom